Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- (-) Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Display Only
Showing 70 Results
Study Finds That Costs Dropped, Outcomes Improved for Major Causes of Death and Illness Between 1995 and 2015
Spending for six of the top seven causes of death and disease over the last 20 years was both cost-effective and improved patient outcomes, according to a study from NPC and RTI Health Solutions…
Personalized Medicine in a World of Value Frameworks
In a commentary published in the Journal of Clinical Pathways, NPC's Dr. Robert W. Dubois explores how to improve value frameworks’ approach to personalized medicine.
Growing Questions About Frameworks Highlight Need for Guiding Practices for Value Assessment
For several years, NPC has kept a close eye on value assessment frameworks and engaging with developers on ways to improve their methodologies, involve patient organizations and use a broad range of…
Amplifying the Migraine Community Voice in ICER Value Assessment Process
In an interview with NPC, Lindsay Videnieks, director of the Headache and Migraine Policy Forum (HMPF), discusses the kind of effort it takes to become involved in the ICER value assessment process,…
Could expanding pre-deductible coverage help those with chronic conditions?
According to a new issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication…
A Precision Paradigm for Value Assessment: How Frameworks Can Account for Personalized Medicine to Inform Payers, Providers, Innovators and Patients
Personalized Medicine Coalition Senior Vice President of Science Policy Daryl Pritchard, PhD, explores personalized medicine and value assessment frameworks.
Considerations When Using ICER's Value Assessments
This week we read with great interest an article posted on the Health Affairs Blog that directly responded to National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois’ Sept. 17…